Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study

Rhea-AI Summary

Ludwig Enterprises, Inc. announces funding for a preclinical study on Glioblastoma, an incurable brain cancer, showing promising results in enhancing traditional cancer therapies by 400%.

Positive

• Exousia AI, a subsidiary of Ludwig Enterprises, Inc., is funding a preclinical study on Glioblastoma (GBM), an aggressive brain cancer.
• The study, led by Dr. Kiminobu Sugaya, aims to develop a more effective treatment for GBM, which has an average lifespan of 12-14 months after diagnosis.
• New research by Dr. Sugaya found that targeting drug-resistant mechanisms in cancer stem cells can enhance the efficacy of traditional cancer therapies by four times against GBM.
• The study will potentially increase the efficacy of Merck's FDA-approved drug Temozolomide in treating GBM by 400%.
• Marvin S. Hausman MD, CEO of Ludwig Enterprises, Inc., expressed confidence in the breakthrough technology and its potential to revolutionize medicine.

Negative

• None.

SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. The study is being done in the lab of Dr. Kiminobu Sugaya PhD, Head of Neuroscience, Burnett School of Biomedical Sciences, University of Central florida, Orlando, Florida. Dr. Sugaya and his research team are developing a more effective way to treat GBM, an aggressive, incurable form of brain cancer.

GBM accounts for 48% of all primary malignant brain tumors and is by far the most aggressive brain cancer with an average lifespan of 12-14 months after diagnosis, if not treated. This devastating brain cancer does not distinguish between people, young or old. Well known individuals who have died of GBM include, Beau Biden, John McCain and Ted Kennedy.

New research led by Dr. Sugaya, a stem cell researcher and neuroscientist, found that targeting a drug resistant mechanism in cancer stem cells significantly enhanced the efficacy of traditional cancer therapies - making them four times more effective against GBM. Current FDA-approved drugs kill less than 25% of glioblastoma cancer stem cells (CSCs). The study sponsored by Exousia AI will employ this unique strategy and potentially increase the efficacy of Merck's FDA approved drug Temozolomide in the treatment of GBM by 400%.

Marvin S. Hausman MD, CEO, stated: "I have thoroughly analyzed Dr. Sugaya's exosome-based targeted drug delivery system many times, and the potential that this breakthrough technology offers. We are embarking on a revolutionary new development in medicine."

About UCF Glioblastoma Study:

https://www.ucf.edu/news/ucf-researchers-develop-novel-therapy-for-incurable-brain-cancer/

About Ludwig Enterprises, Inc.:

Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor and create solutions to prevent chronic inflammation, the causative agent of illnesses which are responsible for more than 50% of deaths worldwide. Exousia AI, a subsidiary has created an Exosomal Targeted Delivery Platform. This transformational technology will lead to the creation of new therapeutics and improve the efficacy of existing treatments.

For more information please visit: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CEO
CEO@LUDG.US
www.ludwigent.com

SOURCE: Ludwig Enterprises, Inc.

View the original press release on accesswire.com

FAQ

What is Ludwig Enterprises, Inc. funding a preclinical study on?

Ludwig Enterprises, Inc. is funding a preclinical study on Glioblastoma (GBM), an aggressive brain cancer.

Who is leading the study on Glioblastoma?

Dr. Kiminobu Sugaya is leading the study on Glioblastoma.

What is the potential increase in efficacy of Merck's FDA-approved drug Temozolomide in treating GBM?

The study aims to potentially increase the efficacy of Temozolomide by 400% in treating GBM.

Who expressed confidence in the breakthrough technology for treating GBM?

Marvin S. Hausman MD, CEO of Ludwig Enterprises, Inc., expressed confidence in the breakthrough technology.